CPU228, a derivative of dofetilide, relieves cardiac dysfunction by normalizing FKBP12.6, NADPH oxidase and protein kinase C ε in the myocardium

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 1, 2010, Pages 77-83

  Hamed, Khan Hussien ^a,b   Hu, Chen ^a   Dai, De Zai ^a   Yu, Feng ^a   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b UNIVERSITY OF ADEN   (Yemen)

Author keywords

CPU228; Dofetilide; FKBP12.6; Isoproterenol; NADPH oxidase; Protein kinase C

Indexed keywords

CPU 228; DOFETILIDE; FK 506 BINDING PROTEIN; GLUTATHIONE PEROXIDASE; ISOPRENALINE; MALONALDEHYDE; PROTEIN KINASE C EPSILON; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART CELL CULTURE; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; QT PROLONGATION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UPREGULATION;

EID: 77949508296     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.62.01.0008     Document Type: Article

References (40)

1. Chelu MG, Wehrens NH. Sarcoplasmic reticulum calcium leak and cardiac arrhythmias. Biochem Soc Trans 2007; 35: 952-956.
2. Saenen JB, Vrints CJ. Molecular aspects of the congenital and acquired long QT syndrome: clinical implications. J Mol Cell Cardiol 2008; 44: 633-646.
3. Patel C, Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 2008; 5: 585-590.
4. Kontula K et al. Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res 2005; 67: 379-387.
5. Liu N et al. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol 2009; 46: 149-159.
6. Pratt CM et al. Mortality in the survival with ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81: 869-876.
7. Riera AR et al. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome. Cardiol J 2008; 15: 209-219.
8. Tomaselli G et al. What causes sudden death in heart failure? Circ Res 2004; 95: 754-763.
9. Kijtawornrat A et al. Use of a failing rabbit heart as a model to predict torsadogenicity. Toxicol Sci 2006; 93: 205-212.
10. Shah RR. If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed? Pharmacol Ther 2008; 119: 215-221.
11. Huang ZJ et al. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits. Clin Exp Pharmacol Physiol 2007; 34: 310-317.
12. Ellison GM et al. Acute beta-adrenergic overload produces myocyte damage through calcium leakage from the ryanodine receptor 2 but spares cardiac stem cells. J Biol Chem 2007; 282: 11 397-11 409.
13. Na T et al. Abrupt changes in FKBP12.6 and SERCA2a expression contribute to sudden occurrence of ventricular fibrillation on reperfusion and are prevented by CPU86017. Acta Pharmacol Sin 2007; 28: 778-782.
14. 2+ leak in chronic heart failure. Circ Res 2008; 103: 1466-1472.
15. Zhang P et al. NADPH oxidase contributes to coronary endothelial dysfunction in the failing heart. Am J Physiol Heart Circ Physiol 2009; 296: H840-H846.
16. Gao G, Dudley S. Redox regulation, NF-kappaB, and atrial fibrillation. Antioxid Redox Signal 2009; 11: 2265-2277.
17. Li N et al. Endothelin receptor antagonist CPU 0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a, a role of hyperphosphorylation of PKC epsilon. Eur J Pharmacol 2008; 590: 2003-2008.
18. 2+ channels and the sarcoplasmic reticulum: alterations during cardiac remodelling. Cardiovasc Res 2008; 77: 315-324.
19. Tereshenko SN et al. The role of amlodipine in the treatment of chronic heart failure in women. Kardiologiia 2007; 47: 56-59.
20. Ochi R, Gupte SA. Ryanodine receptor: a novel therapeutic target in heart disease. Recent Pat Cardiovasc Drug Discov 2007; 2: 110-118.
21. Wehrens XH, Marks AR. Molecular determinants of altered contractility in heart failure. Ann Med 2004; 36: 70-80.
22. Lehmart SE et al. Calstabin deficiency, ryanodine receptors, and sudden cardiac death. Biophys Res Commun 2004; 322: 1267-1279.
23. Zhang X et al. Dissociation of FKBP12.6 from ryanodine receptor type 2 is regulated by cyclic ADP-ribose but not β-adrenergic stimulation in mouse cardiomyocytes. Cardiovasc Res 2009; 84: 253-262.
24. Currie S. Cardiac ryanodine receptor phosphorylation by CaM kinase II: keeping the balance right. Front Biosci 2009; 14: 5134-5156.
25. Zhang GX et al. Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 2007; 42: 804-811.
26. Blum A. Heart failure - new insights. Isr Med Assoc J 2009; 11: 105-111.
27. Redout EM et al. Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species. Cardiovasc Res 2007; 75: 770-781.
28. Pratt CM et al. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol 2006; 48: 471-477.
29. Cheng HC, Incardona J. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts. J Pharmacol Toxicol Methods 2009; 60: 174-184.
30. Venetucci LA et al. The sarcoplasmic reticulum and arrhythmogenic calcium release. Cardiovasc Res 2008; 77: 285-292.
31. Huke S, Bers DM. Ryanodine receptor phosphorylation at serine 2030, 2808 and 2814 in rat cardiomyocytes. Biochem Biophys Res Commun 2008; 376: 80-85.
32. Palaniyandi SS et al. Protein kinase C in heart failure: a therapeutic target? Cardiovasc Res 2009; 82: 229-239.
33. Liu Q et al. Protein kinase Cα, but not PKCβ or PKCγ, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res 2009; 105: 194-200.
34. Liu N et al. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis 2008; 51: 23-30.
35. Seddon M et al. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007; 93: 903-907.
36. Aon AM et al. Mitochondrial oscillations in physiology and pathophysiology. Adv Exp Med Biol 2008; 641: 98-117.
37. Sumitomo N et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66-70.
38. Rosso R et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2007; 4: 1149-1154.
39. +- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007; 117: 2431-2444.
40. 2+ exchange. Cardiovasc Drugs Ther 2009; 23: 207-214.